Franchi F, Rollini F, Faz G, et al. - Given that in patients with prior myocardial infarction, reduction in thrombotic events is seen with vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) but at the cost of increased bleeding, and aspirin withdrawal has emerged as a bleeding reduction strategy, so, researchers undertook the VORA‐PRATIC (Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With Newer Generation P2Y₁₂ Receptor Inhibitors Prasugrel and Ticagrelor) study to determine the pharmacodynamic impacts of vorapaxar with potent P2Y₁₂ inhibitors and the influence of dropping aspirin. This study involved 130 post–myocardial infarction patients receiving standard DAPT (aspirin+prasugrel or ticagrelor), who were randomly assigned to 1 of 3 arms: (1) triple therapy: aspirin+prasugrel/ticagrelor+vorapaxar; (2) dual therapy (drop aspirin): prasugrel/ticagrelor+vorapaxar; (3) DAPT: aspirin+prasugrel/ticagrelor. At baseline and 7 and 30 days, experts conducted pharmacodynamic evaluations. Findings revealed vorapaxar-induced decrease in platelet‐driven global thrombogenicity among post–myocardial infarction patients managed with potent P2Y₁₂ inhibitors, this effect was shown to persist, though attenuated, in the absence of aspirin and without influencing markers of P2Y₁₂ reactivity or clot kinetics.